Read the original article here. Halifax-based Panag Pharma, which is making pain-relief products from natural compounds found in cannabis plants, has agreed to be bought for as much as $27 million by Ontario’s Tetra Bio-Pharma. Based in the Ottawa suburb of Orleans, Tetra is a drug discovery company that specializes in developing treatments based on such compounds – known as cannabinoid-based drug discovery. The company, which is listed on the TSX Venture Exchange, said in a press release that the acquisition will allow Tetra to develop more natural healthcare products and sell them world wide. The Panag Team – which is led by healthcare professionals Mary Lynch, Melanie Kelly and Orlando Hung – will continue to conduct research into cannabinoid-based treatments for Tetra, and receive extra payments for hitting specific milestones. The buyer said it believes it will gain revenues from Panag’s products by late 2019. Continue reading]]>
BIONOVA CONTACT
#46 1344 Summer Street
Halifax, Nova Scotia
Canada B3H 0A8
Phone: 902-421-5705
Fax: 902-421-2733
Email: [email protected]
Halifax, Nova Scotia
Canada B3H 0A8
Phone: 902-421-5705
Fax: 902-421-2733
Email: [email protected]

Recent Posts
- MARS VR Lab
- Workinsights
- NEWS RELEASE: BioNova Announces MycoFutures North Atlantic as the Winner of the Eleventh Annual BioInnovation Challenge (BIC) at BioPort 2021
- NEWS RELEASE: BioNova’s BioPort 2021 Conference for Health and Life Sciences Kicks-Off Today
- NEWS RELEASE: BioNova Selects Eight Semi-Finalists to Participate in the 11th Annual BioInnovation Challenge
Business Wire National BioTech News
- Rapid Dose Therapeutics Closes First Tranche of Private Placement
- Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs
- Circulating Tumor Cell Market Research Report 2022 - ResearchAndMarkets.com
- First Patients Enrolled in IMPACT II Study to Evaluate Attune Medical’s ensoETM for Radiofrequency Ablation Procedures
- FSD Pharma Issues Circular, Adopts Incentive Plan and Grants PSUs
- Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting
- Miravo Healthcare™ Announces Appointment of Dale MacCandlish Weil to its Board of Directors
- Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®
- Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress
- Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
RECENT NEWS
- MARS VR Lab January 25, 2022
- Workinsights January 25, 2022
- NEWS RELEASE: BioNova Announces MycoFutures North Atlantic as the Winner of the Eleventh Annual BioInnovation Challenge (BIC) at BioPort 2021 November 8, 2021
- NEWS RELEASE: BioNova’s BioPort 2021 Conference for Health and Life Sciences Kicks-Off Today November 2, 2021
- NEWS RELEASE: BioNova Selects Eight Semi-Finalists to Participate in the 11th Annual BioInnovation Challenge August 24, 2021
- NEWS RELEASE: BioNova supports the Government of Canada’s biomanufacturing and life sciences strategy July 30, 2021
RECENT TWEETS
Congrats to members @AdaptiivCo on their collaboration deal with printer giant HP 3D Printing and Palo Alto, California medtech specialist Varian. https://t.co/nCJfuIBZXW https://t.co/dYk1Ysyuiy
🎉Congrats to our members Precision BioLogic Inc., leading developers of #hemostasis diagnostic products, on the launch of their new product to improve testing for Hemophilia B
➡️Learn more: https://t.co/l2nsLSTgM7 https://t.co/akuFUMZhzh
➡️Learn more: https://t.co/l2nsLSTgM7 https://t.co/akuFUMZhzh
